Sign Up
Stories
Pharmaceutical Industry Enthusiastic About Cancer Drug Alliances and Bispecific Antibodies
Share
ADOCIA Files 2023 Registration Document
Advanced Ovarian Cancer Treatment Breakt...
Advancements in Antibodies to Protect Im...
Overview
API
Merck and Daiichi Sankyo strike a cancer drug alliance worth up to $22 billion, highlighting the pharmaceutical industry's enthusiasm for antibody-drug conjugates (ADCs). EpimAb Biotherapeutics and Almirall announce a license agreement to develop bispecific antibodies. I-Mab and ABL Bio provide updates on their PD-L1 and 4-1BB bispecific antibody TJ-L14B/ABL503. PharmaEssentia enters into a license agreement with Wuxi Biologics for a myeloid immune checkpoint antibody candidate. Ono Pharmaceutical enters into a drug discovery collaboration with Adimab to discover and develop novel antibody drugs in the oncology field.
Ask a question
How do bispecific antibodies work and what are their potential applications?
What are the key factors that contribute to the success of drug discovery collaborations?
What are the potential benefits of antibody-drug conjugates (ADCs) in cancer treatment?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Apr 2023
Jun 2023
Aug 2023
Coverage